Sustainable development goals One of the main outcomes of the Rio+20 Conference was the agreement by member States to launch a process to develop a set of Sustainable Development Goals SDGs!" which will build upon the #illennium Development Goals and converge with the post 20$% development agenda clic& here for information on different wor& streams!' (t was decided establish an )inclusive and transparent intergovernmental process 1 open to all stakeholders, with a view to developing global sustainable development goals to be agreed by the General Assembly)' (n the Rio+20 outcome document" member States agreed that sustainable development goals SDGs! must* $' +e based on ,genda 2$ and the -ohannesburg .lan of (mplementation' 2' /ully respect all the Rio .rinciples' 0' +e consistent with international law' 1' +uild upon commitments already made' %' Contribute to the full implementation of the outcomes of all ma2or summits in the economic" social and environmental fields' 3' /ocus on priority areas for the achievement of sustainable development" being guided by the outcome document' 4' ,ddress and incorporate in a balanced way all three dimensions of sustainable development and their interlin&ages' 5' +e coherent with and integrated into the 6nited 7ations development agenda beyond 20$%' 8' 7ot divert focus or effort from the achievement of the #illennium Development Goals' $0' (nclude active involvement of all relevant sta&eholders" as appropriate" in the process' (t was further agreed that SDGs must be* ,ction9oriented Concise :asy to communicate ;imited in number ,spirational Global in nature 6niversally applicable to all countries while ta&ing into account different national realities" capacities and levels of development and respecting national policies and priorities' <he outcome document further specifies that the development of SDGs should* +e useful for pursuing focused and coherent action on sustainable development Contribute to the achievement of sustainable development Serve as a driver for implementation and mainstreaming of sustainable development in the 67 system as a whole ,ddress and be focused on priority areas for the achievement of sustainable development <he Rio+20 outcome document The Future We Want resolved to establish an inclusive and transparent intergovernmental process on SDGs that is open to all sta&eholders with a view to developing global sustainable development goals to be agreed by the 67G,' <he outcome document mandated the creation of an inter9governmental Open =or&ing Group" that will submit a report to the 35th session of the General ,ssembly containing a proposal for sustainable development goals for consideration and appropriate action' <he outcome document specifies that the process leading to the SDGs needs to be coordinated and coherent with the processes considering the post 20$% development agenda and that initial input to the wor& of the Open =or&ing Group will be provided by the 67SG in consultation with national governments' 2 C O M P A N Y B A C K G R O U N D A B O U T C O M P A N Y B A C K G R O U N D A B O U T B E X I M C O P H A R M A C E U T I C A L S L T D . B E X I M C O P H A R M A C E U T I C A L S L T D . Beximco Pharmaceuticals Ltd. is a leading edge pharmaceutical company and is a member of the BEXIM! "roup# the largest pri$ate sector industrial conglomerate in Bangladesh. %he strategic strengths of Beximco Pharma are its strong brand recognition# highly s&illed 'or& force and di$ersified business mix. Beximco Pharma brands ( )eoceptin * +*anitidine,# )apa +Paracetamol,# -mdocal +-mlodipine,# )eofloxin +iprofloxacin,# Bexitrol . +/almeterol Plus .luticasone,# Bextrum "old +Multi$itamin and Multi Mineral, and -to$a +-tor$astatin, are among the most recogni0ed brands in the Bangladesh Pharmaceutical industry. Beximco Pharma started its operation in 1123# manufacturing products under the licenses of Bayer -" of "ermany and 4p5ohn Inc. of 4/- and no' has gro'n to become nation6s one of the leading pharmaceutical companies# supplying 178 of country6s total medicine need. %oday Beximco Pharma manufactures and mar&ets its o'n 9branded generics6 for almost all disease ran&ing from -I:/ to cancer# from infection to asthma# from hypertension to diabetes# both nationally and internationally. Beximco Pharma manufactures a range of dosage forms including tablets# capsules# dry syrup# po'der# cream# ointment# suppositories# large $olume intra$enous fluids# metered dose inhalers etc. in se$eral 'orld(class manufacturing plants# ensuring high ;uality standards complying 'ith the <orld =ealth !rgani0ation +<=!, appro$ed current "ood Manufacturing Practices +c"MP,. %he recipient of three times 9gold6 national export trophy# Beximco Pharma is the largest exporter of pharmaceuticals from Bangladesh# spreading its presence in many de$eloping and de$eloped countries across the globe. Beximco Pharma is the only company in Bangladesh to recei$e this highest national accolade for export# for record three times. > Beximco Pharma mar&ets its brands through professional sales and mar&eting teams in -frican# -sian and European mar&ets. It also supplies its products to reno'ned hospitals and institutions in many countries# including *affles =ospital and ? ? <omen @ hildren =ospital in /ingapore# ME:/ and ?enyatta )ational =ospital +?)=, in ?enya# Ainnah =ospital# -gha ?han =ospital and /hau&at ?hanum Memorial =ospital in Pa&istan. Beximco Pharma is also an enlisted supplier of <=! and4)IE.. -nother important business acti$ity of Beximco Pharma is the contract manufacturing for ma5or international brands of leading multinational companies. Beximco Pharma is acclaimed domestically and internationally for its outstanding product ;uality# 'orld class manufacturing facilities# product de$elopment capabilities and outstanding ser$ice. Beximco Pharma has a strong mar&et focus and is anticipating continued future gro'th by le$eraging business capabilities and de$eloping superior product brands and mar&ets. In particular the company is $ery interested in de$eloping a strong export mar&et in 4/- and Europe. %o meet the future demand Beximco Pharma has in$ested 4/B 73 million to build a ne' state(of(the(art manufacturing plant# confirming to 4/.:- and 4? M=*- standards. %his ne' plant 'ill also offer contract(manufacturing facility to leading pharmaceutical companies# especially from Europe and 4/. O R G A N I Z A T I O N A L O R G A N O G R A M O R G A N I Z A T I O N A L O R G A N O G R A M C B E F O R E F I V E Y E A R S S T R A T E G Y B E F O R E F I V E Y E A R S S T R A T E G Y 7 C!" V#$%"& %rust and reliability to the products emerged as one of the core $alues of Beximco Pharmaceuticals Limited. It maintains ;uality in manufacturing of products according to the rules of the <=!. =iring a competent branch of people 'ho are best in their capacity to ser$e the company best# strengthen the BPL function of operation .It also gi$e emphasi0e on promoting ne' products through research and bringing cost efficiency in business operations. Beximco Pharma belie$es that it is in the business 'hich deals 'ith human health 'hich ma&es it more responsible to &eep the highest standards of its products. %hrough its products it tries to deli$er clear benefits to the patients. "ood products# ho'e$er# are only one side of its expression of commitment. BPL belie$es its responsibility lies e$en more in ensuring that the society gets benefited 'hile it continues to gro'. C!'!#(" S)*#$ R"&'+&*,*$*(*"& orporate social responsibility is an integral part of BPLDs business strategy 'hich is reflected in its mission statement. E$ery employee of the company &no's that the company does not $ie' its success and achie$ements in financial terms only# but also in terms of its deep relationship 'ith the society. Each year# an increasing amount of contribution is ploughed bac& into social causes# demonstrating Beximco Pharma6s commitment to the nation. More importantly the company6s contribution extends beyond one(time donation to ongoing participation as reflected in its partnership 'ith )"!s 'or&ing for -I:/ patients# in supporting sports# and in raising disease a'areness among the people. E BPL donated medicines 'orth millions of ta&a to $ictims in national and international calamities. :onation of medicines to $ictims of earth;ua&e in Pa&istan and $ictims of tsunami in /ri Lan&a are 'orth mentioning. %he company maintains a team of scientists 'ho 'or&s as pharmaceutical experts for good go$ernance that gi$e direct benefit to the common people and shareholders. Beximco Pharmaceuticals Limited carefully designed its facilities for reducing ha0ardous impact on the en$ironment through operational excellence pro$iding a friendly en$ironment for a healthy society for tomorro' being the main responsibility of BPL. A F T E R F I V E Y E A R S S T R A T E G Y A F T E R F I V E Y E A R S S T R A T E G Y F M#+%-#)(%!*+. F#)*$*(*"& Located at %ongi# near the capital city :ha&a# BPLDs manufacturing site is spread o$er an area of 23 acres 'hich houses a number of self contained production units including oral solids# metered dose inhalers# intra$enous fluids# li;uids# ointments# creams# suppositories# ophthalmic drops# in5ectables# nebuli0er solutions etc. %he bul& drug unit for producing paracetamol is also located 'ithin this site. ompanyDs penicillin -PI and formulation units are situated at ?alia&oir# a fe' &ms from the main site. %he plant and machinery throughout the site ha$e been designed by and procured mostly from reno'ned European companies. Beximco Pharma has its o'n utility infrastructure to ensure ade;uate generation and distribution of purified 'ater at all times. %he installed capacity of po'er generation is 2 M<. %here is also li;uid nitrogen generation facility on site. /%#$*(0 P$*)0 Beximco Pharmaceutical Limited6s mission is to achie$e business excellence through ;uality by understanding# accepting# meeting and exceeding customer expectations. Beximco Pharmaceutical Limited +BPL, follo's International /tandards on Guality Management /ystem to ensure consistent ;uality of products and ser$ices to achie$e customer satisfaction. BPL also meets all national regulatory re;uirements relating to its current businesses and ensures that current "ood Manufacturing Practices +c"MP, as recommended by <orld =ealth !rgani0ation is follo'ed for its pharmaceutical operations. %he management of BPL commits itself to ;uality as the prime consideration in all its business decisions. -ll employees of BPL must follo' documented procedures to ensure compliance 'ith ;uality standards. 2 %he pool of human resources of the company 'ill be de$eloped to their full potential and harnessed through regular training and their participation in see&ing continuous impro$ement of 'or& methods. E+1*!+2"+(#$ P$*)0 BPL is committed to maintain the harmonious balance of our eco(system and therefore constantly see&s 'ays to manufacture and produce products in an eco(friendly manner so that the balance of nature remains undisturbed and the en$ironment remains sustainable. In pursuit of this goal# BPL 'ill comply fully 'ith all local and national en$ironmental regulations. onser$e natural resources li&e 'ater and energy for sustainable de$elopment# and adopt en$ironmentally safe processes. Ensure appropriate treatment of all effluents prior to discharge# to pre$ent pollution or degradation of en$ironment. Ensure appropriate communication and cooperate 'ith internal and external interested parties on en$ironmental issues. reate a'areness on en$ironmental issues among our employees and suppliers. -dopt modern 'aste management technology. P R E S E N T S T R A T E G I E S P R E S E N T S T R A T E G I E S 1 MARKET POLICY D2"&(*) M#!3"( Being a de$eloping country# the pharmaceutical mar&et and at the same time# the pharmaceutical industry of Bangladesh is gro'ing. In this gro'ing mar&et# BPL has been able to maintain its gro'th through its inno$ati$e mar&eting strategies. In Bangladesh# BPL introduced the concept of ;uality management system by being the first company to achie$e I/! 1331 certification that reflects its commitment to ;uality in e$ery aspect of business. BPL co$ers the health care community of 'hole Bangladesh based in both urban and rural mar&ets# through its 12 strategically located depots. I+("!+#(*+#$ M#!3"( %o fuel the continuous gro'th of BPL# the company has started exploring international mar&ets. %he ;uality of BPL products# strengthened by its I/! 1331 certification# has brought immediate success in 4?# -merica# -ustralia# .rance# Bra0il# India# Pa&istan# /ri Lan&a# Hemen# Myanmar and Iietnam. R".%$#(!0 A''!1#$& 13 %he manufacturing facilities of Beximco Pharma ha$e been audited and appro$ed byJ )ational =ealth /ur$eillance -gency +-)II/-,# Bra0il +M:I, %herapeutic "oods -dministration +%"-,# -ustralia +!/:# M:I and /pray, "ulf entral ommittee for :rug *egistration +for " member states,+!/: @ M:I, Gualified by 4)IE. +M:I @ !/:, Gualified by "lobal "laxo/mith?line +M:I, Gualified by -sthma :rug .acility +-:.,# .rance +M:I, Gualified by "lobal . =off Mann La *oche +!/:, -ppro$als by 4? M=*- and 4/.:- are under process !/:# !ral /olid :osageK M:I# Metered :ose Inhaler R"&"#!)4 & D"1"$'2"+( <ith strong re$erse engineering capability# 'e focus principally on de$eloping high ;uality generic formulations# matching the profile of inno$ator products. <e also focus on simplifying manufacturing processes and impro$ing cost efficiency. !ur gro'ing inno$ation is e$ident from successful launching of a number of ad$anced formulations li&e multi(layer tablets# sustained release formulations# dispersible tablets# melt(in mouth tablets# che'able $itamins etc. In proprietary research# 'e conducted collaborati$e research 'ith iba /pecialty hemicals of /'it0erland. <ith !ur *@: team has successfully de$eloped a range of .(free =.- M:Is. In addition# 'e are also de$eloping a number of -PIs to ensure a$ailability of ra' materials across the range of therapeutic classes. !ur capability to produce hi(tech# speciali0ed niche products as 'ell as drug deli$ery systems has been our core strength to transform BPL into an inno$ation( dri$en generic drug company. 11 C!'!#(" S)*#$ R"&'+&*,*$*(0 ommitment to our society is an integral part of the 'ay 'e are doing business. <e do not 5udge our success in financial terms onlyK 'e $alue e$en more the deep relationship 'ith the society 'e li$e in. Each year# a substantial amount of our earning is ploughed bac& into social causes# so that our society gets benefited 'hile 'e continue to gro'. 5. D+#(*+ - 2"6*)*+"& <e donate and ma&e a$ailable a large ;uantity of medicines to the $ictims of natural disasters# both national and international. Medicines for the $ictims of earth;ua&e in Pa&istan# sunami in /ri Lan&a# and cyclone /I:* in Bangladesh are a fe' 'orth mentioning. 7. P!1*6*+. T!"#(2"+( -! AIDS '#(*"+(& *+ B#+.$#6"&4 *esponding to the needs of thousands of -I:/ patients in the country# 'e are proud to be associated 'ith the initiati$es to pro$ide treatment for these patients. /ince 2337# Beximco Pharma has been supplying -*I drugs through :utch Bangla Ban&# a leading local ban&# for treating the -I:/ patients in Bangladesh. %hese -*I drugs are distributed through -shar -lo# Mu&to -&ash# and onfidential -pproach to -I:/ Pre$ention +--P, ( )"!s 'or&ing for the =IIL-I:/ patients 8. O&"-$% ( -*.4( #.#*+&( A1*#+ #+6 S9*+" F$% /ince its launch in March 233E# !seflu# BPLDs brand of oseltami$ir capsule# has been donated to the go$t. of Bangladesh as 'ell as different reputed organi0ations including I::*#B in response to the pandemic -$ian as 'ell as recent /'ine .lu. <e also supplied !sefluM to the go$ernment of Myanmar as a part of our /* initiati$es 12 C+(!#)( M#+%-#)(%!*+. O''!(%+*(*"& *ising cost of healthcare and medicines has become a global concern# and in order to reduce cost across the $alue chain# pharmaceutical companies from de$eloped mar&ets continue to loo& for suitable partners in de$eloping countries for shifting or outsourcing their production. <ith decades of experience in generic drug manufacturing# 'orld class capabilities as 'ell as significant cost ad$antages# Beximco Pharma can be an ideal partner for you to meet your contract manufacturing needs. /ince its inception# Beximco Pharma has established itself as a reliable partner for a number of 'orld6s leading pharmaceutical companies. %he company has maintained a trac& record of sound professionalism and its management has al'ays adhered to international standards pro$iding a culture and 'or&ing en$ironment similar to that of a multinational company. urrently the company has contract manufacturing agreement 'ith "laxo/mith?line +"/?, for producing Metered :ose Inhaler product. %hese partnerships ha$e pro$ided BPL much $aluable expertise and &no'(ho' to manufacture 'orld(class products. %he company offers significant cost ad$antage as a manufacturer# as the a$erage 'age in Bangladesh is probably the lo'est in the 'orld# and at least t'o to three times lo'er than that in hina or India. Prospecti$e partners can benefit themsel$es 'ith competiti$e ad$antages li&e a$ailability of highly s&illed manpo'er at a $ery lo' cost# lo' energy cost# "o$t. policy support# in$estor friendly en$ironment etc. 1> -fter &no'ing the 'hole strategic management techni;ues follo'ed by Beximco Pharma it is clear that# no company can follo' one form or approach from the corporate le$el strategy. /ituations $ary and so does the business strategies to meet the demand at a gi$en point of time. =o'e$er# Beximco Pharma has also been that of a &ind 'here they practiced different types of gro'th strategies# reached boom and at the same time company follo'ed to the need for reco$ery stage 'here they ha$e gone through the rene'al strategy. But more or less it can be said that Beximco Pharma preferred either gro'th through mar&et de$elopments and if not so then stabilityK 'ith a consistent approach to'ards consumer. <ell the sum up of the case study can be stated as that 'ith all their superior strategies and techni;ues they ha$e continued to stay prosperous from centuries and also hope to maintain that throughout. 1C